Zevtera® (ceftobiprole medocaril)
Bacterial infections
Approved/CommercialMarketed
Key Facts
About Basilea Pharmaceutica
Founded in 2000, Basilea Pharmaceutica is a Swiss biopharma company dedicated to addressing the critical global health challenge of antimicrobial resistance. The company has successfully transitioned to a commercial-stage entity with two approved and marketed products, Cresemba and Zevtera, generating revenue and operating profit. With a focused pipeline, strategic collaborations like its BARDA partnership, and a commitment to ESG principles, Basilea is strategically positioned for growth in the specialized anti-infectives market.
View full company profileTherapeutic Areas
Other Bacterial infections Drugs
| Drug | Company | Phase |
|---|---|---|
| Novel Antibiotics | Shionogi | Various |
| Anti-infectives Portfolio | Aurobindo Pharma | Commercial |
| Azithromycin products | Alkem Laboratories | Commercial |
| Cefixime & Ofloxacin combinations | Ipca Laboratories | Commercial |
| Antibiotic Portfolio | SPIMACO | Approved/Commercial |
| Cephalosporin APIs (Cefixime, Cefpodoxime, etc.) | Nectar Lifesciences | Approved |
| Penicillin APIs (Amoxicillin, etc.) | Nectar Lifesciences | Approved |
| Vibativ® (telavancin) | Cleo Life Sciences | Approved |